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Abstract Article Info 
Introduction: Undifferentiated nasopharyngeal carcinoma is the most common malignant tumor in 
nasopharynx, in which most patients come to a hospital in advanced stage. Cisplatin is one of the most effective 
widely used chemotherapy drugs for advanced stage undifferentiated nasopharyngeal carcinoma. Although it 
provides a successful outcome against cancer, there is serious side effect namely ototoxic hearing loss. Ginkgo 
biloba is a powerful antioxidant which may prevent ototoxic hearing loss. 
Objective: The study aims to determine the effect of ginkgo biloba against ototoxic hearing loss on advanced 
stage undifferentiated nasopharyngeal carcinoma receiving cisplatin chemotherapy.  
Methods: This study was double blind Randomized Control Trial with pre-post test design, was conducted in 
22 patients with advanced stage undifferentiated nasopharyngeal carcinoma receiving cisplatin chemotherapy 
at the Department of Otorhinolaryngology Head and Neck Surgery dr. Moewardi Hospital Surakarta between 
June 1st and October 1st 2019. The subjects were allocated into control (plasebo) and treatment (80 mg Ginkgo 
biloba extract) groups. Hearing function was examined with pure tone audiometry, tympanometry and Distortion 
Product Otoacoustic Emission before and after the first, the second and the third cisplatin chemotherapy. The 
results of the examination of the two groups were tested using Friedman and Chi Square test. P value of <0.05 
was considered significant. 
Results: The study subjects were mostly male (63.6%), with the age range of 40-59 years (90.9%). The baseline 
characteristics of the study subjects were homogeneous (p>0.05). There was a significant difference in the 
incidence of ototoxic hearing loss between control and treatment group after getting the second and the third 
chemotherapy (p=0.043 and p=0.033, respectively). 
Conclusion: There is a significant effect of ginkgo biloba in term of preventing ototoxic hearing loss on 
advanced stage undifferentiated nasopharyngeal carcinoma patients receiving cisplatin chemotherapy. 
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1. INTRODUCTION 
Nasopharyngeal carcinoma (NPC) is a malignant tumor derived 
from epithelial/ mucosal lining the surface of the nasopharynx, which 
remains a problem in medicine field. Nasopharyngeal carcinoma is the 
most common malignancy in Ear Nose and Throat (ENT) cancer it ranks 
the fourth highest among all types of malignancies. Nowadays it has 
been reported that the prevalence of NPC in Indonesia is 6.2 per 
100.000 population annually[1]. Based on medical records of 
dr.Moewardi Hospital Surakarta between 2012 and 2014 there were 298 
new cases of nasopharyngeal carcinoma in ENT Oncology [2].  
WHO classifies NPC into three criteria based on cell 
differentiation, namely type 1 (keratinized squamous cell carcinoma), 
type 2 (non-keratinized carcinoma), and type 3 (poorly differentiated/ 
undifferentiated carcinoma). WHO type 3 occupies the highest 
percentage compared to two others [1,3]. 
The early symptoms of NPC are atypical, and some have no 
symptoms, so that most patients come to the hospital with an advanced 
stage (stage III or IV). The majority of advanced stage undifferentiated 
NPC patients receive radiotherapy and chemotherapy[3,4]. Cisplatin is 
one of the most effective widely used chemotherapy drugs for advanced 
stages undifferentiated NPC [5,6]. Although cisplatin provides a 
successful outcome against cancer, it has serious side effects, one of 
them is ototoxic hearing loss. The ototoxic effect of cisplatin is bilateral 
sensorineural hearing loss, which is progressively irreversible, started 
from 6000-8000 Hz frequencies that eventually and will continue to 
decline if the therapy is continued and it is accompanied by tinnitus [7]. 
Previous studies reported that the incidence of cisplatin ototoxicity is 
between 75 and 100% depending on the age, the dose and the number 
of cisplatin chemotherapy cycles [8].  
Early detection of hearing disorder due to drug ototoxicity is very 
important so that we can change the dose, the drug or prescribe 
antioxidant in order to avoid more severe sensorineural hearing loss 
[6,7,9]. 
Ginkgo biloba is a powerful antioxidant, which contains extracts of 
ginkgo biloba (EGb 761) 24% flavone glycosides, 6% terpene lactones, 
and 7% proanthocyaniclines. Flavone glycosides and terpene lactones 
play pivotal role in inhibiting free radicals, so that oxidative stress and 
apoptosis of the cells can be prevented [6,7,10]. As antioxidants, ginkgo 
biloba 761 extract has proven otoprotective to ototoxicity caused by 
cisplatin examined with Distortion Product Otoacoustic Emission 
(DPOAE) examination [11,12]. 
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Picture 1. The mechanism of ginkgo biloba in preventing ototoxic 
hearing loss of cisplatin 
Ginkgo biloba inhibits Cisplatin-induced Reactive Oxygen Species 
(ROS) elevation by hindering oxidative nicotinamide adenine dinucleotide 
phosphate (NADPH) formation. In addition, ginkgo biloba also prevents 
endoplasmic reticulum stress and DNA damage, so that caspase-12 and P53 
decrease. By inhibiting the endoplasmic reticulum stress, DNA damage and 
increased ROS, ginkgo biloba reduces apoptosis process of outer hair cells 
(OHC), so hearing loss will not occur (Picture 1). 
The increasing incidence of ototoxic hearing loss in patients with 
advanced stage undifferentiated NPC receiving cisplatin chemotherapy, 
encouraged the author to seek additional therapy by using Ginkgo biloba to 
prevent or to abate ototoxic hearing loss, without attenuating the efficacy of 
cisplatin in chemotherapy. Hence the patients can have good quality of life 
by having good hearing function.  
2. MATERIAL AND METHODS 
This research is an double-blind randomized controlled trial (RCT) with pre-
post test design, was conducted at ENT department of dr.Moewardi Hospital 
Surakarta between  June 1st and October 1st 2019. The subjects were 22 patients 
with advanced stage undifferentiated NPC that receiving cisplatin and fulfilling 
inclusion and exclusion criteria. The inclusion criteria were patients aged 18-59 
years, never received ginkgo biloba or other antioxidants, and willing to join the 
study by signing the informed consent. Patients with the history of chemotherapy 
and radiotherapy, received other ototoxic therapy, had perforation of tympanic 
membrane, sensorineural hearing loss before chemotherapy, renal failure, hepatic 
insufficiency, and or work in the noisy area were excluded from this study. 
Subjects were randomly assigned into two groups, control and treatment 
groups by using simple Microsoft Excel. The control group receive 
chemotherapy cisplatin-paclitaxel with additional therapy placebo 1 tablet per 
day, while the treatment group receive chemotherapy cisplatin-paclitaxel with 
additional therapy ginkgo biloba 80 mg per day orally. This additional therapy 
was given 1 day before chemotherapy for 45 days. Hearing examination was 
performed with pure tone audiometry, tympanometry, and DPOAE before and 
after the first, the second and the third cisplatin chemotherapy.  
Non parametric statistical data were analyzed with Friedman test. The 
categorical data were analyzed with Chi Square and Fisher Exact Tests. The p 
value of <0.05 was considered significant. 
This study was approved by the Research Ethics Committee, Faculty of 
Medicine, Sebelas Maret University/ dr.Moewardi Hospital Surakarta by issuing 
of ethical clearance documents (Ethical Approval Number: 
760/VI/HREC/2019). 
3. RESULT  
During the study period, we found 22 advanced stage undifferentiated 
NPC patients who fulfilled our inclusion criteria. These subjects were 
randomly assigned into control (n=11) and treatment (n=11) groups. The 
baseline characteristic of both groups were homogenous. Thus there were 
no significant differences between the two groups (p>0.05) (Table 1).  
 
Table 1. Baseline Characteristics of Research Subjects 
Characteristics Control 
n (%) 
Treatment 
n (%) 
P 
Sex    
Male 7 (63.6) 7 (63.6) 1,000*) 
Female 4 (36.4) 4 (36.4)  
Age    
18-39 y.o 2 (18.2) 0 (0) 0.098**) 
40-59 y.o 9 (81.8) 11 (100)  
Mean ± SD 49.09 ± 8.81 54.27 ± 4.52  
Profession    
Labor 2 (18.2) 2 (18.2) 0.639*) 
Housewives 3 (27.3) 2 (18.2)  
Trader 4 (36.3) 2 (18.2)  
Retired 0 (0) 1 (9.1)  
Farmer 2 (18.2) 4 (36.3)  
NPC Stage    
III 3 (27.3) 1 (9.1) 0.726*) 
IVa 2 (18.2) 2 (18.2)  
IVb 2 (18.2) 3 (27.3)  
IVc 4 (36.3) 5 (45.4)  
Cisplatin Dose    
80-120 mg 11 (100) 9 (81.8) 0.476*) 
>120 mg 0 (0) 2 (18.2)  
Note: *) Fisher Exact Test  
    **) Independent Sample t-Test 
 
Table 1 explains that the gender of the both subjects groups were mostly 
male, with jobs as traders or farmers. Research subjects who came to the 
hospital were mostly have stage IVc, and received a dose of cisplatin 
chemotherapy is 80-120 mg.  Then the Fisher Exact test was performed with 
a result of p>0.05 which means that there was no significant relationship 
between the control group and the treatment group, or the characteristics of 
the study subjects were homogeneous. 
The research subjects in the control group were mostly 40-59 years old 
(81.8%), while in the treatment group all the study subjects were 40-59 years 
old (100%). Shapiro-will test was performed to determine the normality of 
data distribution, with the results of p=0.62 (p>0.05) which means the data 
is normally distributed. Then the statistical analysis test was performed with 
an independent sample t-test to determine whether there were differences in 
the mean age in the control and treatment groups, the results were p=0.98 
(p>0.05) which meant there were no significant differences, so the subjects 
of this study were homogeneous. 
Table 2. Tympanometry Examination Results 
 
Tympanometry 
Results 
Control  
n (%) 
Treatment           
n (%) 
P* 
Right ear     
 Type A 2 (18.2) 3 (27.3) 1.000 
 Type B 9 (81.8) 8 (72.7)  
Left ear     
 
Type A 2 (18.2) 3 (27.3) 1.000 
 Type B 9 (81.8) 8 (72.7)  
Note: * Fisher Exact Test 
Tympanometry examination performed in the control and the treatment 
groups obtained no significant differences between the two groups 
(p=1.000). Tympanometry results in both groups were mostly type B for the 
left and the right ears (Table 2).  
Table 3. The Results of DPOAE Examination 
DPOAE  
(REFER) 
Control 
n (%) 
Treatment 
n (%) 
p 
Pre Chemo 0 (0) 0 (0) - 
Post Chemo 1 3 (27.3) 0 (0) 0.214*) 
Post Chemo 2 7 (63.4) 1 (9.1) 0.024*) 
Post Chemo 3 9 (81.8) 3 (27.3) 0.010**) 
Note: *) Fisher Exact Test 
    **) Chi Square Test 
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 None of the subjects in both groups undergoing DPOAE examination 
before chemotherapy had "REFER". Post first cisplatin chemotherapy 3 
subjects in control group had "REFER" and none in treatment group 
(p=0.214). This finding (REFER) increased in both groups in post 
chemotherapy 2 and 3, they were 7 and 9 in control group and 1 and 3 in 
treatment group (p=0.024 and p=0.010, respectively) (Table 3). 
The significant differences between the two groups were observed 
started at post second chemotherapy. More subjects in control group had 
DPOAE finding of REFER than those in treatment group. 
Table 4. Ototoxic Hearing Loss Control Group and Treatment Group 
Ototoxic Hearing Loss Control 
n (%) 
Treatment 
n (%) 
p 
Pre Chemo 0 (0) 0 (0)               - 
Post Chemo 1 3 (27.3) 0 (0) 0.214a 
Post Chemo 2 6 (54.5) 1 (9.1) 0.043a 
Post Chemo 3 8 (72.7) 3 (27.3) 0.033b 
Note: a Fisher Exact Test 
    b Chi Square Test 
Based on American Speech-Language Hearing Association (ASHA) criteria 
we found more subjects with ototoxic hearing loss in control group than those in 
treatment group. Statistical test results of both groups show p value of 0.214 
(p>0.05) for the first cisplatin chemotherapy, which means there was no 
difference significant  incidence of ototoxic hearing loss on control and treatment 
group. The second and third post-chemotherapy obtained p value of 0.043 and 
0.033 (p<0.05), showed a difference significant incidence of ototoxic hearing loss 
on control and treatment group (Table 4).  
4. DISCUSSION 
In our study we analyzed the incidence of ototoxic hearing loss before and 
after cisplatin chemotherapy in patients with advanced stage undifferentiated 
NPC. These patients were randomly assigned into control and treatment 
groups. For the control group we gave cisplatin-paclitaxel only while the 
treatment group we administered cisplatin-paclitaxel plus ginkgo biloba. 
Most of our study subjects were male with the age ranged from 40 to 59 
years old. This finding is similar to that of Jayalie et al study in Cipto 
Mangunkusumo Hospital Jakarta. They reported that 68.3% of NPC patients 
were males and 80.2% were in the age of over 30 years old. Barata as well as 
Whitehorn et al in 2014 also reported that male was more predominant than 
female among NPC patients (55% and 73.8%, respectively). 
Distortion Product Otoacoustic Emission (DPOAE) is a quick and 
objective electrophysiologic tool to determine the state and the function of 
cochlear outer hair cells. It also can detect response at high frequencies. 
"REFER" in DPOAE examination demonstrates the damaged function of 
cochlear outer hair cell [7,12]. 
Our DPOAE examination obtained less "REFER" results in our subjects 
receiving additional therapy of Ginkgo biloba. This is also an evidence that 
cisplatin ototoxicity impact hearing function significantly. In our study 81.8% 
subjects in control group suffered from hearing loss after their third 
chemotherapy with cisplatin-paclitaxel. Putri et al study also reported that 
DPOAE can detect early events of cisplatin ototoxicity (100%). 
The effect of ototoxic hearing loss can also be detected by pure tone 
audiometry examination. Based on ASHA criteria it is regarded ototoxic 
hearing loss if there are one of the three following criteria: 1). Decrease ≥20 
dB at least one frequency, 2). Decrease ≥10 dB at least two adjacent 
frequencies, 3). Loss of response on three successive frequencies that are on 
previous checks are still responding [13,14]. 
Pure tone audiometry examination performed in our study subjects 
demonstrated that the incidence of ototoxic hearing loss was higher in control 
group than that of in treatment group. This result is similar to that of done with 
DPOAE examination. Therefore, pure tone audiometry can be recommended 
for detecting ototoxic hearing loss, especially in patients with advanced stage 
undifferentiated NPC. 
Ginkgo biloba is a powerful antioxidant which plays an important role in 
preventing ototoxic hearing loss due to cisplatin by inhibiting the formation of 
free radical [10,15]. In our study, adding ginkgo biloba to cisplatin-paclitaxel 
can prevent or reduce the incidence of ototoxic hearing loss in patients with 
advanced stage undifferentiated NPC receiving cisplatin chemotherapy. This 
is in accordance with the study by Sampaio et al (2016), which reported that 
ginkgo biloba significantly prevented sensorineural hearing disorders in 
malignant tumor patients undergoing cisplatin chemotherapy. Dias et al (2015) 
who conducted a study in cancer patients found a significant decrease in 
hearing threshold at the frequency of 8 KHz in subjects who did not receive 
ginkgo biloba as compared to them in treatment group who had ginkgo biloba.  
Choi et al study also stated that ginkgo biloba extract significantly prevented 
cochlear outer hair cell damage due to cisplatin and inhibited down regulation 
of Gap Junctional Intercellular Communication (GJIC). Gap Junctional 
Intercellular Communication disorders play important role in the mechanism 
of ototoxic hearing loss induced by cisplatin. It has been proven that ginkgo 
biloba has proapoptosis activity againts NPC and does not interfere cisplatin 
anti tumor activity, it also owns no side effect.  
5. CONCLUSION 
There is a significant effect of ginkgo biloba in term of preventing 
ototoxic hearing loss on advanced stage undifferentiated NPC patients 
receiving cisplastin chemotherapy. Ginkgo biloba is safe as it has no side 
effect. Therefore adding Ginkgo biloba to cisplatin chemotherapy can be 
benificial for patients with advanced stage undifferentiated NPC so that their 
quality of life improves since they have good hearing function. 
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